Patents for A61P 35 - Antineoplastic agents (221,099)
04/2006
04/25/2006CA2194885C Substituted benzamidines, their preparation and their use as pharmaceutical compounds
04/20/2006WO2006042104A2 Calixarene-based peptide conformation mimetics, methods of use, and methods of making
04/20/2006WO2006041961A1 Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same
04/20/2006WO2006041197A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR δ
04/20/2006WO2006041135A1 STAT3 PHOSPHORYLATION INHIBITOR AND Notch1 EXPRESSION INHIBITOR
04/20/2006WO2006041119A1 Hydrazide derivatives
04/20/2006WO2006041037A1 Novel pyridine derivative
04/20/2006WO2006040940A1 Intestinal polyp inhibitor
04/20/2006WO2006040914A1 Process for producing concentrate of unsaturated fatty acid
04/20/2006WO2006040646A1 Benzimidazole or indole amides as inhibitors of pin1
04/20/2006WO2006040579A1 Bioactive polymers
04/20/2006WO2006040569A1 Thiophene amide compounds for use in the treatment or prophylaxis of cancers
04/20/2006WO2006040568A1 Quinoxalines as b raf inhibitors
04/20/2006WO2006040526A1 Quinazoline derivatives for use against cancer
04/20/2006WO2006040522A1 Quinoline derivatives
04/20/2006WO2006040281A1 Thiazolyl-dihydro indazoles
04/20/2006WO2006040279A1 Pi3 kinases
04/20/2006WO2006040196A1 4-hydroxy tamoxifen gel formulations
04/20/2006WO2006040056A1 Heterocyclic substituted bisarylurea derivatives as kinase inhibitors
04/20/2006WO2006040052A1 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity
04/20/2006WO2006040050A1 Quinazolinylmethylene thiazolinones as cdk1 inhibitors
04/20/2006WO2006040049A1 Novel azaindole thiazolinones as anti-cancer agents
04/20/2006WO2006040047A2 Diagnostics and therapeutics for diseases associated with rho/rac-interacting citron kinase (cit)
04/20/2006WO2006040039A1 N,n'-dithenylurea derivatives used in the form of kinase inhibitors
04/20/2006WO2006040036A1 Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
04/20/2006WO2006039807A1 Methods and therapeutic compositions comprising plant extracts for the treatment of cancer
04/20/2006WO2006039806A1 Depression of herg k+ channel function in mammalian cells and applications to the control of cancer cells division
04/20/2006WO2006021888A3 Dihydrofolate reductase inhibition by epigallocatechin gallate compounds
04/20/2006WO2006021335A3 Peptide mixture from peptides having a molecular weight of from 1000 to 5000 dalton
04/20/2006WO2006021002A3 Compounds useful for inhibiting chk1
04/20/2006WO2006014903A3 Compositions and methods of use for adam12 antagonists in treating disease
04/20/2006WO2006013420A3 Mixture of catechins or rather polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy (bph)
04/20/2006WO2006009755A3 Azaindoles modulating c-kit activity and uses therefor
04/20/2006WO2005123115A8 Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
04/20/2006WO2005120588A3 Peptides delivered to cell nuclei
04/20/2006WO2005112969A3 Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
04/20/2006WO2005082357A8 Use of beta-lapachone for treating hematologic tumors
04/20/2006WO2005033098A8 Salts and polymorphs of a pyrrole-substituted indolinone compound
04/20/2006WO2005030705A9 Inhibitors of histone deacetylase
04/20/2006WO2005023255A3 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process
04/20/2006WO2004044164A3 Method for identifying risk of melanoma and treatments thereof
04/20/2006US20060084819 Total synthesis of myriaporones
04/20/2006US20060084809 Compounds as PDE IV and TNF-inhibitors
04/20/2006US20060084698 Methods for preparation and use of psorospermin analogs
04/20/2006US20060084688 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
04/20/2006US20060084667 New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them
04/20/2006US20060084661 IL-8 receptor antagonists
04/20/2006US20060084646 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
04/20/2006US20060084626 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
04/20/2006US20060084621 Compositions and methods for inhibiting expression of anti-apoptotic genes
04/20/2006US20060084614 Anticoagulants; bioavailability, lower toxicity; 1-(glycosyl substituted phenylmethylamino)-4-amidino-benzene derivatives
04/20/2006US20060084613 Dipeptide enzyme inhibitor; antiinflammatory agents; autoimmune disease; wound healing agents
04/20/2006US20060084612 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
04/20/2006US20060084610 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
04/20/2006US20060084600 Human homologues of fused gene
04/20/2006US20060084595 Complex comprising OCIF and polysaccharide
04/20/2006US20060084148 April-a novel protein with growth effects
04/20/2006US20060084143 Screen for agonists and antagonists; treat solid tumors, vascular deficiencies; polypeptide, polynucleotide, plasmid; chemotherapeutic agents, alkylating agents, antimetabolites, vinca alkaloids, plant extracts, nitrosoureas, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants
04/20/2006US20060084141 Biosynthetic gene cluster for the maytansinoid antitumor agent ansamitocin
04/20/2006US20060084135 Compositions for manipulating the lifespan and stress response of cells and organisms
04/20/2006US20060084118 Lymphocytes; transcription factors; interferons; diagnosis of autoimmune disease such as lupus
04/20/2006US20060083792 Utilizing nanocrystalline silver metal, alloy or compound for localized tissue infections; reducing side effects; limiting overuse of antibiotics
04/20/2006US20060083784 Amorphous pharmaceutical compositions
04/20/2006US20060083778 Controlled release compositions of estradiol metabolites
04/20/2006US20060083745 Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
04/20/2006US20060083740 By modulating the expression of mutant and wild type CD83 gene products produced in a mammal; regulation of T cell and dendritic cell activity; antibodies
04/20/2006US20060083739 Treating prostate cancer with anti-ErbB2 antibodies
04/20/2006US20060083711 Methods and products related to the intracellular delivery of polysaccharides
04/20/2006US20060083684 Method of radio-labelling biomolecules
04/20/2006DE3991505B4 Somatostatinpeptide, deren Analoga oder Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen Somatostatin peptides, their analogues or derivatives, to processes for their preparation and pharmaceutical compositions containing them
04/20/2006DE202005015707U1 Kräuterzusammensetzung zur Behandlung von Krebs Herb composition for the treatment of cancer
04/20/2006DE19830167B4 Neue Azatyrosin-Analoga New azatyrosine analogues
04/20/2006DE102004050952A1 Use of a beta-3-adrenoreceptor-agonist for the prophylaxis and/or treatment of e.g. benign prostata hyperplasia and/or its associated symptoms and chronic pelvic base pain syndrome, pelvic myoneuropathy, prostatodynia or prostatopathy
04/20/2006DE102004050910A1 Composition containing phospholipid, sterol and negative charge carrier, useful e.g. for treating parasitic diseases and tumors, acts by stimulating leucopoiesis
04/20/2006DE102004050196A1 Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament Substituted 2-pyridone derivatives, processes for their preparation and their use as a medicament
04/20/2006DE102004049910A1 Composition for photodynamic therapy or diagnosis, useful for treating cancer and skin disorders, comprises chlorin e6, purpurin 5 and poly(vinyl pyrrolidone)
04/20/2006DE102004049622A1 Novel para-sulfonamido-substituted 2-anilinopyrimidines are useful in a wide range of medicaments and as cell cycle kinase inhibitors or receptor tyrosine kinase inhibitors
04/20/2006CA2626049A1 Methods and therapeutic compositions comprising plant extracts for the treatment of cancer
04/20/2006CA2597341A1 Depression of herg k+ channel function in mammalian cells and applications to the control of cancer cells division
04/20/2006CA2584185A1 Heterocyclic substituted bisarylurea derivates as kinase inhibitors
04/20/2006CA2584179A1 N,n'-diphenylurea derivatives which are suitable as kinase inhibitors
04/20/2006CA2583499A1 Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
04/20/2006CA2583311A1 Quinazolinylmethylenethiazolinones as cdk1 inhibitors
04/20/2006CA2583192A1 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity
04/20/2006CA2583096A1 Quinoxalines as b raf inhibitors
04/20/2006CA2583092A1 Antiangiogenic calixarene-based peptide mimetics
04/20/2006CA2582986A1 Novel azaindole thiazolinones as anti-cancer agents
04/20/2006CA2582985A1 Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
04/20/2006CA2581516A1 Quinazoline derivatives
04/20/2006CA2579288A1 Thiazolyldihydroindazoles
04/20/2006CA2579279A1 Tricyclic thiazole derivatives as pi3 kinases
04/20/2006CA2577598A1 Modulators of hepatocyte growth factor activator
04/19/2006EP1647599A2 Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation
04/19/2006EP1647277A1 Glycoside-containing liposome
04/19/2006EP1647271A1 4-Hydroxy tamoxifen gel formulations
04/19/2006EP1647256A1 Dendritic cell infiltrativity activating composition and immune activator
04/19/2006EP1646869A2 Compositions and methods for the therapy and diagnosis of lung cancer
04/19/2006EP1646656A2 Human antibody molecules for il-13
04/19/2006EP1646649A1 7a5/prognostin and use thereof for the diagnostic and therapy of tumors
04/19/2006EP1646639A2 Nucleotide phosphoramidates as anticancer agents